D-Penicillamine in the Neonatal Period: Past (!), Present (!?) and Future (?!)

Lakatos Lajos

doi:10.23937/2469-5769/1510047

Abstract

D-penicillamine (D-PA) was first recognized as a potential benefit for neonatal hyperbilirubinemia (NHBI) caused by hemolytic diseases of the newborn infant or immaturity of UDP-glucuronyltransferase enzyme. During a long-term follow up study there was a remarkedly low incidence of retrolental fibroplasia (RLF) in the infants treated with D-PA in their neonatal period.

Highlights

D-PENICILLAMINE (D-PA) was first isolated as an amine from the degradation products of penicillin by Abraham, et al in 1942 [1]
During a long-term follow up study there was a remarkedly low incidence of retrolental fibroplasia (RLF) in the infants treated with D-PA in their neonatal period
All infants < 1500 g birthweight were treated with D-PA to prevent retinopathy of prematurity (ROP)

Summary

Introduction

D-PENICILLAMINE (D-PA) was first isolated as an amine from the degradation products of penicillin by Abraham, et al in 1942 [1]. During a long-term follow up study there was a remarkedly low incidence of retrolental fibroplasia (RLF) in the infants treated with D-PA in their neonatal period.

Results

Conclusion